11:26 AM EST - InMed Pharmaceuticals Inc. : Has filed a Patent Cooperation Treaty application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a priority date from May 8, 2018 (PCT/CA2018/050548). The PCT filing, which is a conversion from the provisional patent filed in May 2017, is an important step in providing intellectual and commercial protection for this therapy. InMed Pharmaceuticals Inc.
shares T.IN are trading up $0.14 at $1.14.
